Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.
Number of pages:15
KOL Highlights Include:
Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.
Tykerb (lapatinib, NVS) has poor efficacy relative to Kadcyla (Roche) in HER2-positive patients, and results from studies attempting to expand Tykerb usage to different or earlier lines of therapy have not been impressive.
Neratinib (PBYI) would need to be better than Kadcyla to garner significant usage in the metastatic setting.
Kadcyla tolerability is probably better than Herceptin + chemotherapy, so favorable results in studies of Kadcyla in early breast cancer could increase Kadcyla usage.
This oncologist’s practice does not use Avastin (Roche) despite its presence in the NCCN guidelines, partly due to the lack of OS benefit.
MammaPrint (Agendia) sometimes gives results that are difficult to interpret and discordant with information generated by Oncotype (Genomic Health, Inc.) and information from this oncologist’s expertise.
Public awareness has led to an increase in BRCA screening, and BRCA screening would increase further if a PARP inhibitor with a BRCA-mutation population in its label were approved.
Preliminary results from palbociclib (PFE) are favorable and exciting, and this physician would give letrozole+palbociclib to most eligible patients.
Past results for therapeutic vaccines for breast cancer do not give this oncologist optimism for the field.
Halaven (ESALY) has good efficacy as a single-agent cytotoxic in advanced breast cancer.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.